Lior Shaltiel

Amministratore Delegato presso NUREXONE BIOLOGIC INC.

Patrimonio netto: 158 950 $ in data 31/05/2024

Health Technology

Posizioni attive di Lior Shaltiel

Società	Posizione	Inizio	Fine
NUREXONE BIOLOGIC INC.	Direttore/Membro del Consiglio	15/06/2022	-
NUREXONE BIOLOGIC INC.	Amministratore Delegato	01/04/2021	-
NurExone Biologic Ltd. NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022.	Direttore/Membro del Consiglio	01/04/2021	-
	Amministratore Delegato	01/04/2021	-

Distribuzione geografica

Israele	2
Canada	2

Posizioni

Director/Board Member	2
Chief Executive Officer	2

Settori

Health Technology

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
NUREXONE BIOLOGIC INC.	Health Technology

Aziende private	1
NurExone Biologic Ltd. NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022.	Health Technology

Aziende private

Health Technology